Thursday, November 24, 2016

We cant get rid of Alzheimers yet, but we can keep trying.

Alzheimer's is probably one of the worst diseases anyone can deal with. Although we have yet to find a treatment for Alzheimer's, we can keep trying until we find something. Solanezumab was an experimental Alzheimers drug that promised to slow down the deterioration of thinking and memory, which failed in a large Eli Lilly clinical trial. This was very upsetting to those that were hoping to be treated. The drug was prescribed to those that had mild dementia, the drug was supposed to detect it early on and try to slow down the symptoms. People that develop Alzheimer's sometimes do not show any symptoms. Testing a drug on people that have developed a disease before showing symptoms is challenging and costly.

Image result for normal brain and alzheimer's brain amyloid buildup
Solanezumab has also failed in two big clinical trials involving patients with mild or moderate Alzheimers. When Lily reported that the results of those trials , it showed that the drug did have an effect in some patients with mild symptoms. So then they started another trial with 2, 100 patients with mild dementia due to Alzheimer's.

Dr. Eric Reiman, executive director of the Banner Alzheimers Institute raised questions about the drug, he wondered whether Lilly's dose was high enough,whether the researchers were attacking the right form of amyloid, and whether they were treating the patients too late in the disease process. I agree with Dr.Reiman on this, in order for us to attack a disease such as Alzheimer's, we must do research from every angle possible. The treatment for Alzheimer's is probably very close by, but we are just looking in the wrong places. They can start off by fully understanding Alzheimer's from top to bottom, and one of the main causes which are amyloid buildup, which is the buildup of proteins in the brain. We can work on a drug that tries to deteriorate amyloid buildup as it begins to develop in the brain.

No comments:

Post a Comment